-- 週四,原油期貨價格回落,布蘭特原油期貨早盤一度突破每桶126美元大關,因為交易員擔心美伊戰爭將導致長期供應短缺。 近月穆爾班原油期貨下跌3.4%,至每桶109.61美元;布蘭特原油期貨下跌3.3%,至每桶114.11美元,早盤一度觸及每桶126美元的高點。 澳新銀行分析師表示:“隨著供應短缺加劇,布蘭特原油價格跌破每桶120美元。” 澳新銀行補充道:“由於霍爾木茲海峽無限期關閉的前景令市場情緒承壓,原油價格的上漲勢頭沒有放緩的跡象。” 外交關係的破裂,加上川普總統指示做好長期封鎖的準備,使得交易員們擔心長期供應短缺,而僅靠需求下降可能無法彌補這一缺口。 「美伊談判破裂,加上據報川普總統拒絕了伊朗關於重新開放霍爾木茲海峽的提議,令市場對石油供應迅速恢復失去希望,」荷蘭國際集團(ING)表示。 「儘管我們估計需求下降幅度約為160萬桶/日,這固然可觀,但顯然不足以彌補我們目前面臨的供應缺口,」荷蘭國際集團補充道。 市場依賴現有庫存的能力正在迅速下降。 分析公司Kpler的數據顯示,伊朗僅剩下12至22天的未使用儲存能力。 一旦這些設施滿載運轉,德黑蘭將被迫額外削減每日150萬至160萬桶的產量。 此次即將到來的減產將疊加在因海峽關閉而已停產的約1000萬桶/日的產量之上。 荷蘭國際集團(ING)分析師警告稱,儘管區域需求下降幅度估計約為160萬桶/日,但仍不足以彌補不斷擴大的供應缺口,這意味著大幅提價可能是平衡市場的唯一手段。 美國能源資訊署(EIA)週三發布的周報顯示,截至4月24日當週,美國原油庫存下降620萬桶至4.595億桶,供應趨緊的跡象顯現。 同時,據報道,川普週三表示,阿聯酋退出歐佩克的決定可能有助於緩解能源價格上漲。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%